Drug Trial Radar · NCT07920211
Two Trials to Evaluate TEV-53408 in Participants With Non-Segmental Vitiligo
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,020
Planned (sponsor's estimate)
Start
Nov 16, 2026
Primary completion
Sep 12, 2030
Study completion Jun 19, 2031
Sponsor
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D LLCTeva (TEVA)
- Sponsor type
- Industry
- First posted
- Nov 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of these clinical trials is to learn if TEV-53408 can help adults with Non-Segmental Vitiligo (NSV). Vitiligo causes patches of skin to lose their color. The main questions the trials aim to answer are: Can TEV-53408 help bring color back to the skin on the face? Can TEV-53408 help bring color back to the skin on the body? What side effects may happen with TEV-53408? TEV-53408 will be compared with placebo to see if it helps bring color back to the skin. Participants will: Receive TEV-53408 or placebo as an injection under the skin Have their skin checked during the trials Answer questions about how vitiligo affects their daily life Have blood tests and other health checks
Conditions
- Vitiligo
Interventions
TEV-53408 Dose ADrug
Injectable- Subcutaneous administration.
TEV-53408 Dose BDrug
Injectable- Subcutaneous administration.
PlaceboDrug
Injectable- Subcutaneous administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Trial 1: Proportion of Participants Achieving a ≥75% Reduction in Facial Vitiligo Area Scoring Index (F-VASI75)Time frame: Baseline, Week 24
- Trial 2: Proportion of Participants Achieving F-VASI75Time frame: Baseline, Week 48
- Trial 2: Proportion of Participants Achieving T-VASI50 (US Only)Time frame: Baseline, Week 48
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.